{"id":1815,"date":"2018-12-31T00:00:44","date_gmt":"2018-12-30T17:00:44","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=1815"},"modified":"2018-12-31T00:00:44","modified_gmt":"2018-12-30T17:00:44","slug":"efficacy-and-liver-fibrosis-improvement-in-compensated-cirrhotic-patients-with-chronic-hcv-genotypes-1-and-6-infection-with-and-without-hiv-co-infection-receiving-the-combination-regimen-of-grazoprevi","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/1815\/","title":{"rendered":"Efficacy and liver fibrosis improvement in compensated cirrhotic patients with chronic HCV genotypes 1 and 6 infection with and without HIV co-infection receiving the combination regimen of Grazoprevir and Elbasvir"},"content":{"rendered":"\n\t\t\t\t\n<p class=\"wp-block-paragraph\"><strong>Project no.: <\/strong>HIV-NAT 245<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Brief Summary: <\/strong>This study will evaluate the safety and efficacy of combination\ntreatment with grazoprevir + elbasvir for compensated cirrhotic participants\nwith chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV)\ninfection with or without human immunodeficiency virus (HIV) infection. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total 100 patients with compensated cirrhosis,\nchronically infected with HCV GT1 or GT6 with or without HIV infection will be\nincluded. Patients with HCV GT1 and GT6 will be enrolled on a 1:1 basis\n(approximately 50 patients with GT1 and 50 patients with GT6). Treatment-na\u00efve\npatients will be treated with the combination of grazoprevir plus elbasvir for\n12 weeks. Treatment-experienced patients, including null responders, partial\nresponders or post\u00adtreatment relapsers, will be assigned to treat with the\ncombination plus weight\u00adbased RBV for 16 weeks. The dosages of study drugs are\n100 mg of grazoprevir once daily and 50 mg of elbasvir once daily. All patients\nwill follow up to assess SVR (defined by HCV RNA level &lt;12 IU\/mL) at week12\nand week 24 after treatment (SVR12 and SVR24, respectively). Additionally,\nparticipants will be evaluated the longitudinal changes in LS values by TE up\nto 240 weeks (5 years) after treatment.<\/p>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\t\t\t\tThis study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV) infection with or without human immunodeficiency virus (HIV) infection. \t\t<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-1815","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=1815"}],"version-history":[{"count":0,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1815\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=1815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=1815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=1815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}